Gazdar, Adi F.
Bunn, Paul A.
Minna, John D.
Article History
First Online: 1 December 2017
Change Date: 10 November 2017
Change Type: Corrigendum
Change Details: There were errors in two sentences within the section ‘Epigenetic changes in SCLC’, indicating that EZH2 suppresses ASCL1 expression by suppression of TGFβ signalling. Instead, EZH2 promotes ASCL1 expression by suppression of TGFβ signalling. This has been corrected in the online and print versions of the article.
Competing interests
: J.D.M. and A.F.G. receive licensing fees for the lung cancer cell lines they have established. P.A.B. serves as a consultant and advisory board member for AstraZeneca.